Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT00004190. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I(Limited)/Phase II Study of Oxaliplatin (OXAL) and Gemcitabine (GEMZAR) in Patients With Metastatic Pancreatic Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and oxaliplatin in treating patients who have refractory locally advanced or metastatic pancreatic cancer.
Study identification
- NCT ID
- NCT00004190
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 59 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 1999
- Primary completion
- Mar 31, 2003
- Completion
- May 31, 2003
- Last update posted
- Jul 13, 2016
1999 – 2003
United States locations
- U.S. sites
- 18
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CCOP - Scottsdale Oncology Program | Scottsdale | Arizona | 85259-5404 | — |
| CCOP - Illinois Oncology Research Association | Peoria | Illinois | 61602 | — |
| CCOP - Carle Cancer Center | Urbana | Illinois | 61801 | — |
| CCOP - Cedar Rapids Oncology Project | Cedar Rapids | Iowa | 52403-1206 | — |
| CCOP - Iowa Oncology Research Association | Des Moines | Iowa | 50309-1016 | — |
| Siouxland Hematology-Oncology | Sioux City | Iowa | 51101-1733 | — |
| CCOP - Wichita | Wichita | Kansas | 67214-3882 | — |
| CCOP - Ann Arbor Regional | Ann Arbor | Michigan | 48106 | — |
| CCOP - Duluth | Duluth | Minnesota | 55805 | — |
| Mayo Clinic Cancer Center | Rochester | Minnesota | 55905 | — |
| CentraCare Clinic | Saint Cloud | Minnesota | 56303 | — |
| CCOP - Missouri Valley Cancer Consortium | Omaha | Nebraska | 68131 | — |
| Quain & Ramstad Clinic, P.C. | Bismarck | North Dakota | 58501 | — |
| CCOP - Merit Care Hospital | Fargo | North Dakota | 58122 | — |
| CCOP - Toledo Community Hospital Oncology Program | Toledo | Ohio | 43623-3456 | — |
| CCOP - Geisinger Clinical and Medical Center | Danville | Pennsylvania | 17822-2001 | — |
| Rapid City Regional Hospital | Rapid City | South Dakota | 57709 | — |
| CCOP - Sioux Community Cancer Consortium | Sioux Falls | South Dakota | 57105-1080 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Pancreatic Cancer trials
Other public records listing Pancreatic Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07817147: CREO - Microwave Ablation Feasibility Study Recruiting
- NCT07805954: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma Recruiting
- NCT07796997: GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy Not yet recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT06141031: Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting
- NCT05394259: A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00004190, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 13, 2016 · Synced Sep 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00004190 live on ClinicalTrials.gov.